These initial symptoms often escalate within 24-48 hours , leading to hypercalcemia (a dangerous buildup of calcium in the blood) and acute kidney failure
From available case reports, compounding pharmacy data, and practitioner experience, the following have been observed: BPC-157 Reported Side Effects Nausea and gastrointestinal discomfort (especially with oral administration) Dizziness or light-headedness Flushing or warmth at injection sites Headache Fatigue or somnolence in some users TB-500 Reported Side Effects Injection site reactions (redness, mild pain, swelling) Transient fatigue or lethargy following administration Headache Possible flu-like symptoms in a minority of users Long-Term Risks: What We Don't Know This is arguably the most vital part of this guide
5-Amino-1-methylquinolinium iodide, NNMTi, CID 66522933
As always, please reach out to our care team at [email protected] with any questions
It is better to have too much than too little
Contraindications and Precautions Do NOT use AOD-9604 if you: Are pregnant, trying to conceive, or breastfeeding (no safety data in pregnancy/lactation) Have active cancer or history of malignancy (peptide effects on existing cancer unknown) Are under 18 years of age (pediatric safety not established) Have known hypersensitivity to peptides or benzyl alcohol (in bacteriostatic water) Have severe kidney or liver disease without physician clearance Use with caution and enhanced monitoring if you have: Diabetes or glucose metabolism disorders (monitor blood sugar closely despite no expected impact) Cardiovascular disease (comprehensive cardiac evaluation recommended) Thyroid disorders (monitor thyroid function during therapy) History of migraines (may increase headache frequency in susceptible individuals) Drug Interactions Limited formal drug interaction studies exist for AOD-9604
